Table 1.
Main patient characteristics (N:45)
| Characteristic | N (%) |
|---|---|
| Age | |
| Median | 45 |
| Range | 32–69 |
| Menopausal status | |
| Pre | 33 (73.3) |
| Post | 12 (26.7) |
| BMI | |
| <25 | 29 (64.4) |
| ≥25 | 16 (35.6) |
| Tumor size | |
| T0 | 2 (4.4) |
| T2 | 13 (28.8) |
| T3 | 15 (33.3) |
| T4 | 15 (33.3) |
| Clinical stage | |
| IIA | 3 (6.7) |
| IIB | 13 (28.9) |
| IIIA | 16 (35.5) |
| IIIB | 13 (28.9) |
| Grading | |
| G2 | 3 (6.7) |
| G3 | 25 (55.6) |
| Unknow | 17 (37.8) |
| Ki67 | |
| ≤14% | 4 (8.9) |
| >15% | 31 (68.8) |
| Unknow | 10 (22.2) |
| Estrogen receptor status | |
| Positive | 23 (51.1) |
| Negative | 22 (48.9) |
| Progesterone receptor status | |
| Positive | 17 (37.8) |
| Negative | 28 (62.2) |
| Triple positive tumors | 17 (37.8) |
| HER2 status | |
| Overexpressed | 34 (75.6) |
| Amplified | 11 (24.4) |
The DECT trial. BMI, body mass index.